Interaction between SNCA gene polymorphisms and T2DM with Parkinson's disease.
Adult
Aged
Alcohol Drinking
/ genetics
Diabetes Mellitus, Type 2
/ complications
Female
Gene-Environment Interaction
Genetic Predisposition to Disease
/ genetics
Genotype
Humans
Logistic Models
Male
Middle Aged
Parkinson Disease
/ complications
Polymorphism, Single Nucleotide
alpha-Synuclein
/ genetics
Parkinsons disease
T2DM
interaction
single nucleotide polymorphisms
Journal
Acta neurologica Scandinavica
ISSN: 1600-0404
Titre abrégé: Acta Neurol Scand
Pays: Denmark
ID NLM: 0370336
Informations de publication
Date de publication:
Nov 2020
Nov 2020
Historique:
received:
16
03
2020
revised:
20
05
2020
accepted:
28
05
2020
pubmed:
3
6
2020
medline:
13
1
2021
entrez:
3
6
2020
Statut:
ppublish
Résumé
To investigate the association of several single nucleotide polymorphisms (SNPs) within alpha-synuclein (SNCA) gene and additional gene-environment interaction with Parkinson's disease (PD) risk. Hardy-Weinberg equilibrium (HWE) is tested for controls using SNPstats (http://bioinfo.iconcologia.net/SNPstats). Logistic regression is used to calculate the ORs (95% CI) for relations between the four SNPs and PD risk. The generalized multifactor dimensionality reduction (GMDR) model is used to evaluate the synergy between gene and environment. A total of 1161 people were included in this study, including 386 cases of PD and 775 normal controls. In this study, the genotype frequency of the control group was consistent with HWE distribution. Rs356219-G allele frequency was 30.0% in patients and 19.8% in control group. The rs356221-T allele frequency was 29.7% in the patients and 20.8% in the control group. Rs356219-G and rs356221-T alleles were associated with increased PD risk, with adjusted ORs (95% CI) of 1.92 (1.28-2.52) and 1.52 (1.05-2.02), respectively. We also found no significant correlation between rs2301134 and rs2301135 and susceptibility to PD. The best gene-environment interaction models were determined by GMDR analysis, which shown a significant gene-T2DM interaction combinations, but the gene-alcohol drinking interaction combinations were all not significant. We also conducted stratified analysis for interaction effect using logistic regression. We found that T2DM patients with rs356221-AT/ TT genotype have the highest PD risk, compared to subjects with rs356219-AA genotype, OR (95%CI) = 2.67 (1.83-3.46). The rs356219-G and rs356221-T, gene-environment interaction between rs356221 and T2DM were all associated with increased PD risk.
Substances chimiques
SNCA protein, human
0
alpha-Synuclein
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
443-448Subventions
Organisme : Science and Technologic Innovation Talents
ID : 51282
Organisme : Natural Science Foundation of Shandong Province
ID : ZR2019MH065
Informations de copyright
© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Fahn S. Description of Parkinson’s disease as a clinical syndrome. Ann N Y Acad Sci. 2003;991:1-14.
de Rijk MC, Launer LJ, Berger K, Breteler MM, Dartigues JF, Baldereschi M. Prevalence of Parkinson’s disease in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology. 2000;54:S21-S23.
Wood-Kaczmar A, Gandhi S, Wood NW. Understanding the molecular causes of Parkinson’s disease. Trends Mol Med. 2006;12(11):521-528.
Nalls MA, Pankratz N, Lill CM, et al. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson’s disease. Nat Genet. 2014;46(9):989-993.
Kalinderi K, Bostantjopoulou S, Fidani L. The genetic background of Parkinson’s disease: current progress and future prospects. Acta Neurol Scand. 2016;134(5):314-326.
Wu Y, Zhang Y, Han X, Li X, Xue L, Xie A. Association of VEGF gene polymorphisms with sporadic Parkinson’s disease in Chinese Han population. Neurol Sci. 2016;37(12):1923-1929.
Gupta SP, Kamal R, Mishra SK, Singh MK, Shukla R, Singh MP. Association of polymorphism of neuronal nitric oxide synthase gene with risk to Parkinson’s Disease. Mol Neurobiol. 2016;53(5):3309-3314.
Li XX, Liao Q, Xia H, Yang XL. Association between Parkinson's disease and G2019S and R1441C mutations of the LRRK2 gene. Exp Ther Med. 2015;10(4):1450-1454.
Liu X, Zhu R, Xiao T, Li Q, Zhu Y, He Z. An updated analysis with 45,078 subjects confirms the association between SNCA rs11931074 and Parkinson’s disease. Neurol Sci. 2018;39(12):2061-2069.
Fang J, Yi K, Guo M, et al. Analysis of LRRK2, SNCA, and ITGA8 Gene variants with sporadic Parkinson’s disease susceptibility in Chinese Han population. Parkinsons Dis. 2016;2016:3474751.
Bendor JT, Logan TP, Edwards RH. The function of α-synuclein. Neuron. 2013;79(6):1044-1066.
Eisbach SE, Outeiro TF. Alpha-Synuclein and intracellular trafficking: Impact on the spreading of Parkinson’s disease pathology. J Mol Med (Berl). 2013;91(6):693-703.
Lashuel HA, Overk CR, Oueslati A, Masliah E. The many faces of Alpha -synuclein: from structure and toxicity to therapeutic target. Nat Rev Neurosci. 2013;14(1):38-48.
Davila-Ortiz de Montellano DJ, Rodriguez-Violante M, Fresan A, Monroy-Jaramillo N, Yescas-Gomez P. Frequency of single nucleotide polymorphisms and alpha-synuclein haplotypes associated with sporadic Parkinsons disease in the Mexican population. Rev Neurol. 2016;63(8):345-350.
Davis AA, Andruska KM, Benitez BA, Racette BA, Perlmutter JS, Cruchaga C. Variants in GBA, SNCA, and MAPT influence Parkinson disease risk, age at onset, and progression. Neurobiol Aging. 2016;37(209):e1-209.
Shahmohammadibeni N, Rahimi-Aliabadi S, Jamshidi J, et al. The analysis of association between SNCA, HUSEYO and CSMD1 gene variants and Parkinson’s disease in Iranian population. Neurol Sci. 2016;37(5):731-736.
Wu-Chou YH, Chen YT, Yeh TH, et al. Genetic variants of SNCA and LRRK2 genes are associated with sporadic PD susceptibility: a replication study in a Taiwanese cohort. Parkinsonism Relat Disord. 2013;19(2):251-255.
Mizuta I, Satake W, Nakabayashi Y, et al. Multiple candidate gene analysis identifies -synuclein as a susceptibility gene for sporadic Parkinson’s disease. Hum Mol Genet. 2006;15(7):1151-1158.
Allam MF, Del Castillo AS, Navajas RF. Parkinson’s disease risk factors: genetic, environmental, or both? Neurol Res. 2005;27(2):206-208.
Bettiol SS, Rose TC, Hughes CJ, Smith LA. Alcohol consumption and Parkinson’s disease risk: a review of recent findings. J Parkinsons Dis. 2015;5(3):425-442.
De Pablo-Fernandez E, Breen DP, Bouloux PM, Barker RA, Foltynie T, Warner TT. Neuroendocrine abnormalities in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2017;88:176-185.
Athauda D, Foltynie T. Insulin resistance and Parkinson’s disease: a new target for disease modification? Prog Neurogibol. 2016;145-146:98-120.
De Pablo-Fernandez E, Sierra-Hidalgo F, Benito-León J, Bermejo-Pareja F. Association between Parkinson’s disease and diabetes: Data from NEDICES study. Acta Neurol Scand. 2017;136(6):732-736.
Cereda E, Barichella M, Pedrolli C, et al. Diabetes and risk of Parkinson’s disease: a systematic review and meta- analysis. Diabetes Care. 2011;34:2614-2623.
Biosa A, Outeiro TF, Bubacco L, Bisaglia M. Diabetes mellitus as a risk factor for Parkinson’s Disease: a molecular point of view. Mol Neurobiol. 2018;55(11):8754-8763.
Miyake Y, Tanaka K, Fukushima W, et al. Fukuoka Kinki Parkinson's Disease Study Group. SNCA polymorphisms, smoking, and sporadic Parkinson’s disease in Japanese. Parkinsonism Relat Disord. 2012;18(5):557-561.
Gao J, Nalls MA, Shi M, et al. An exploratory analysis on gene-environment interactions for Parkinson disease. Neurobiol Aging. 2012;33(10):2528.e1-6.
Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinic opathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55:181-184.
Genuth S, Alberti KG, Bennett P, et al. Follow-up report on the diagnosis of diabetes mellitus, The expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 2003;26:3160-3167.
Sharma M, Ioannidis JPA, Aasly JO, et al. Large-scale replication and heterogeneity in Parkinson disease genetic loci. Neurology. 2012;79(7):659-667.
Campêlo CLDC, Silva RH. Genetic variants in SNCA and the risk of sporadic Parkinson’s disease and clinical outcomes: a review. Parkinsons Dis. 2017;2017:4318416.
Wider C, Vilariño-Güell C, Heckman MG, et al. Ross, SNCA, MAPT, and GSK3B in Parkinson disease: a gene-gene interaction study. Eur J Neurol. 2011;18(6):876-881.
Mata IF, Leverenz JB, Weintraub D, et al. APOE, MAPT, and SNCA genes and cognitive performance in Parkinson disease. JAMA Neurol. 2014;71(11):1405-1412.
Emelyanov A, Andoskin P, Yakimovskii A, et al. SNCA, LRRK2, MAPT polymorphisms and Parkinson’s disease in Russia. Parkinsonism Relat Disord. 2013;19(11):1064-1065.
Li X, Li W, Liu G, Shen X, Tang Y. Association between cigarette smoking and Parkinson’s disease: a meta-analysis. Arch Gerontol Geriatr. 2015;61(3):510-516.
Costa J, Lunet N, Santos C, Santos J, Vaz-Carneiro A. Cafeine exposure and the risk of Parkinson’s disease: a systematic review and meta-analysis of observational studies. J Alzheimers Dis. 2010;20(Suppl 1):S221-S238.
Zhang P, Tian B. Metabolic Syndrome: An Important Risk Factor for Parkinson’s Disease. Oxid Med Cell Longev. 2014;2014:729194.